ES2462921T3 - Sales de lercanidipino - Google Patents

Sales de lercanidipino Download PDF

Info

Publication number
ES2462921T3
ES2462921T3 ES05776228.8T ES05776228T ES2462921T3 ES 2462921 T3 ES2462921 T3 ES 2462921T3 ES 05776228 T ES05776228 T ES 05776228T ES 2462921 T3 ES2462921 T3 ES 2462921T3
Authority
ES
Spain
Prior art keywords
lercanidipine
crystalline
salt
besylate
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05776228.8T
Other languages
English (en)
Spanish (es)
Inventor
Amedeo Leonardi
Gianni Motta
Markus Von Raumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Recordati Ireland Ltd
Recordati Industria Chimica e Farmaceutica SpA
Original Assignee
Recordati SA
Recordati Ireland Ltd
Recordati Industria Chimica e Farmaceutica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA, Recordati Ireland Ltd, Recordati Industria Chimica e Farmaceutica SpA filed Critical Recordati SA
Application granted granted Critical
Publication of ES2462921T3 publication Critical patent/ES2462921T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ES05776228.8T 2004-08-24 2005-08-22 Sales de lercanidipino Expired - Lifetime ES2462921T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
US604149P 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (1)

Publication Number Publication Date
ES2462921T3 true ES2462921T3 (es) 2014-05-26

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05776228.8T Expired - Lifetime ES2462921T3 (es) 2004-08-24 2005-08-22 Sales de lercanidipino

Country Status (19)

Country Link
US (1) US7683179B2 (https=)
EP (1) EP1799644B1 (https=)
JP (1) JP2008510754A (https=)
KR (1) KR20070045351A (https=)
CN (1) CN101048379A (https=)
AR (1) AR050467A1 (https=)
AU (1) AU2005276619B2 (https=)
BR (1) BRPI0514606A (https=)
CA (1) CA2575078A1 (https=)
EA (1) EA011773B1 (https=)
ES (1) ES2462921T3 (https=)
IL (1) IL180905A0 (https=)
MX (1) MX2007002141A (https=)
NO (1) NO20071515L (https=)
NZ (1) NZ553127A (https=)
PE (1) PE20060629A1 (https=)
TW (1) TW200613275A (https=)
WO (1) WO2006021397A1 (https=)
ZA (1) ZA200702364B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100926247B1 (ko) * 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
CA2654230C (en) 2006-06-12 2012-09-11 Novartis Ag Process for making a lactate salt of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
IN2009DN05509A (https=) * 2007-03-14 2010-04-30 Teva Pharma
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
WO2009070311A2 (en) 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine fumarate
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20100105743A1 (en) * 2008-08-01 2010-04-29 Gopal Krishna Pharmaceutical compositions and methods for stabilizing the same
PL2320740T3 (pl) * 2008-08-01 2014-09-30 The Medicines Co Kompozycje farmaceutyczne klewidypiny oraz sposoby ich wytwarzania z niskim stężeniem zanieczyszczeń
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011121452A2 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
EP4524132A4 (en) * 2022-05-10 2026-04-22 Myrodia Therapeutics Co Ltd 2-METHYL-2-THIAZOLINE SALT

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5767136A (en) 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
IL180905A0 (en) 2007-07-04
EA200700492A1 (ru) 2007-08-31
AU2005276619B2 (en) 2009-04-30
KR20070045351A (ko) 2007-05-02
NO20071515L (no) 2007-05-22
EA011773B1 (ru) 2009-06-30
ZA200702364B (en) 2008-09-25
EP1799644A1 (en) 2007-06-27
TW200613275A (en) 2006-05-01
US7683179B2 (en) 2010-03-23
MX2007002141A (es) 2007-04-27
CA2575078A1 (en) 2006-03-02
PE20060629A1 (es) 2006-08-11
WO2006021397A1 (en) 2006-03-02
AR050467A1 (es) 2006-10-25
CN101048379A (zh) 2007-10-03
NZ553127A (en) 2009-07-31
BRPI0514606A (pt) 2008-06-17
US20060047125A1 (en) 2006-03-02
WO2006021397A8 (en) 2006-04-27
AU2005276619A1 (en) 2006-03-02
EP1799644B1 (en) 2014-02-12
JP2008510754A (ja) 2008-04-10

Similar Documents

Publication Publication Date Title
ES2462921T3 (es) Sales de lercanidipino
US12172960B2 (en) Organic compound salts
ES2334678T3 (es) Nueva foprma cristalina de hidrocloruro de lercanidipino y procedimiento para su preparacion.
US6852737B2 (en) Crude and crystalline forms of lercanidipine hydrochloride
AU2002327924A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
CN100494175C (zh) 盐酸乐卡地平的溶剂合物和盐酸乐卡地平的晶形
RU2146672C1 (ru) Способ получения 3-этил-5-метил(±)2[2-аминоэтокси)-метил]-4-(2-хлорфенил)-1,4-дигидро- 6-метил-3,5-пиридиндикарбоксилат монобензолсульфоната
CA2399459C (en) Novel crude and crystalline forms of lercanidipine hydrochloride
HK40105022A (en) Crystalline hydrobromide salt of 5-meo-dmt
HK40105022B (en) Crystalline hydrobromide salt of 5-meo-dmt
CA2380202A1 (en) Novel crude and crystalline forms of lercanidipine hydrochloride
HK1140487B (en) Pharmaceutical compositions containing crystalline form (i) of lercanidipine hydrochloride
KR20130033243A (ko) 아데포비어 디피복실의 공결정